Hemab Therapeutics (NASDAQ:COAG) Coverage Initiated by Analysts at Wedbush

Analysts at Wedbush initiated coverage on shares of Hemab Therapeutics (NASDAQ:COAG) in a research report issued to clients and investors on Tuesday, Marketbeat.com reports. The brokerage set an “outperform” rating and a $42.00 price target on the stock. Wedbush’s price target indicates a potential upside of 62.22% from the stock’s current price.

Other analysts have also issued research reports about the company. The Goldman Sachs Group began coverage on Hemab Therapeutics in a research note on Tuesday. They set a “buy” rating and a $36.00 price objective on the stock. Jefferies Financial Group began coverage on Hemab Therapeutics in a research note on Tuesday. They set a “buy” rating and a $39.00 price objective on the stock. Finally, Wall Street Zen raised Hemab Therapeutics to a “hold” rating in a research note on Saturday, May 9th. Four analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $41.75.

Hemab Therapeutics Stock Performance

Hemab Therapeutics stock opened at $25.89 on Tuesday. Hemab Therapeutics has a fifty-two week low of $23.00 and a fifty-two week high of $36.61.

Hemab Therapeutics (NASDAQ:COAG) last posted its quarterly earnings data on Thursday, May 21st. The company reported ($23.98) EPS for the quarter.

Insider Transactions at Hemab Therapeutics

In other Hemab Therapeutics news, major shareholder Ra Capital Management, L.P. purchased 3,802 shares of the firm’s stock in a transaction on Tuesday, May 19th. The shares were purchased at an average cost of $24.97 per share, with a total value of $94,935.94. Following the purchase, the insider owned 6,375,972 shares in the company, valued at approximately $159,208,020.84. This represents a 0.06% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Over the last quarter, insiders bought 2,902,872 shares of company stock valued at $53,769,784.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company’s research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab’s pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.